Last reviewed 2026-04-20 · How we verify

Reblozyl

At a glance

Approved indications

• Myelodysplastic syndrome
• beta Thalassemia

Common side effects

• Headache
• Bone Pain
• Arthralgia
• Fatigue
• Cough
• Abdominal Pain
• Diarrhea
• Dizziness
• Influenza
• Nausea
• Viral Upper Respiratory Infection
• Musculoskeletal Pain

Serious adverse events

• Cerebrovascular Accident
• Deep Vein Thrombosis
• Acute Myeloid Leukemia (AML M6)

Key clinical trials

• A Trial Comparing Three Different Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A MyeloMATCH Treatment Trial) (PHASE2)
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
• A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia (PHASE2)
• ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
• Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA (PHASE1, PHASE2)
• Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) (PHASE1, PHASE2)
• Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients (PHASE2)
• Luspatercept in Patients Affected With Rare Inherited Anemias (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.